ClinicalTrials.gg

Program

GSK3882347

A development code.

In GlaxoSmithKline's pipeline, FimH antagonist. Its studies are mostly in Urinary Tract Infections, led by GlaxoSmithKline.

Furthest: phase 1, since Jul 23, 20203 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline30 open or runningphase 1since Jul 23, 2020Jul 23, 2020none ahead
  • Named in GlaxoSmithKline’s own pipeline as GSK3882347, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2020First study: phase 1 study in Urinary Tract InfectionsFirst studyNCT04488770 · 61 enrolled · United Kingdom
  2. Nov 15, 2021Phase 1 study in Urinary Tract InfectionsNCT05138822 · 140 enrolled · United States
  3. Feb 27, 2023Phase 1 study in Urinary Tract InfectionsNCT05760261 · 27 enrolled · United Kingdom

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“FimH antagonist”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05760261Urinary Tract Infections · United Kingdom1CompletedAug 13, 202427
NCT05138822Urinary Tract Infections · United States1CompletedDec 3, 2024140
NCT04488770Urinary Tract Infections · United Kingdom1CompletedMay 14, 202161

How it is read

Names in the registry

  • “GSK3882347”, 3 entries

Codes read as this program: GSK3882347.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.